Cliff Asness's OCUL Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 499,339 shares of Ocular Therapeutix, Inc. (OCUL) worth $4.23 M, representing 0.00% of the portfolio. First purchased in 2017-Q3, this long-term strategic position has been held for 26 quarters.
Based on 13F filings, Cliff Asness has maintained a strategic position in OCUL, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2026, adding 318,616 shares. Largest reduction occurred in Q1 2023, reducing 70,092 shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's Ocular Therapeutix (OCUL) Holding Value Over Time
Track share changes against reported price movement
Quarterly Ocular Therapeutix (OCUL) Trades by Cliff Asness
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +318,616 | Add 176.30% | 499,339 | $8.47 |
| Q4 2025 | +34,847 | Add 23.89% | 180,723 | $12.14 |
| Q3 2025 | +34,854 | Add 31.39% | 145,876 | $11.69 |
| Q2 2025 | +95,372 | Add 609.41% | 111,022 | $9.28 |
| Q1 2025 | -10,629 | Reduce 40.45% | 15,650 | $7.33 |
| Q4 2024 | +8,791 | Add 50.27% | 26,279 | $8.54 |
| Q3 2024 | +17,488 | New Buy | 17,488 | $8.70 |
| Q2 2024 | -11,755 | Sold Out | 0 | $0.00 |
| Q1 2024 | -40,473 | Reduce 77.49% | 11,755 | $9.10 |
| Q4 2023 | -14,976 | Reduce 22.28% | 52,228 | $4.46 |
| Q3 2023 | +24,974 | Add 59.14% | 67,204 | $3.14 |
| Q2 2023 | -288 | Reduce 0.68% | 42,230 | $5.16 |
| Q1 2023 | -70,092 | Reduce 62.24% | 42,518 | $5.27 |
| Q4 2022 | +99,628 | Add 767.43% | 112,610 | $2.81 |
| Q3 2022 | -22,360 | Reduce 63.27% | 12,982 | $4.16 |
| Q2 2022 | +6,947 | Add 24.47% | 35,342 | $4.02 |
| Q1 2022 | +6,675 | Add 30.73% | 28,395 | $4.97 |
| Q4 2021 | -42,962 | Reduce 66.42% | 21,720 | $6.95 |
| Q3 2021 | +6,007 | Add 10.24% | 64,682 | $10.00 |
| Q2 2021 | -6,402 | Reduce 9.84% | 58,675 | $14.18 |
| Q1 2021 | +16,291 | Add 33.39% | 65,077 | $16.41 |
| Q4 2020 | -7,829 | Reduce 13.83% | 48,786 | $20.70 |
| Q3 2020 | -16,595 | Reduce 22.67% | 56,615 | $7.61 |
| Q2 2020 | +73,210 | New Buy | 73,210 | $8.33 |
| Q4 2017 | -21,256 | Sold Out | 0 | $0.00 |
| Q3 2017 | +21,256 | New Buy | 21,256 | $6.16 |
Cliff Asness's Ocular Therapeutix Investment FAQs
Cliff Asness first purchased Ocular Therapeutix, Inc. (OCUL) in Q3 2017, acquiring 21,256 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held Ocular Therapeutix, Inc. (OCUL) for 26 quarters since Q3 2017.
Cliff Asness's largest addition to Ocular Therapeutix, Inc. (OCUL) was in Q1 2026, adding 499,339 shares worth $4.23 M.
According to the latest 13F filing for Q1 2026, Cliff Asness's firm, Aqr Capital Management LLC, owns 499,339 shares of Ocular Therapeutix, Inc. (OCUL), valued at approximately $4.23 M.
As of the Q1 2026 filing, Ocular Therapeutix, Inc. (OCUL) represents approximately 0.00% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.
Cliff Asness's peak holding in Ocular Therapeutix, Inc. (OCUL) was 499,339 shares, as reported at the end of Q1 2026.